Medco Research Institute to Spearhead PGx Projects; Warfarin Study Results to be Released in March

Pharmacy-benefits manager Medco this week outlined some activities planned for the Medco Research Institute, which is spearheading the company's pharmacogenomics research efforts. Additionally, during the company's 2009 earnings call, officials discussed the acquisition of DNA Direct and the forthcoming release of results from a study looking at PGx-guided warfarin dosing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.